Recently, Westlake Therapeutics (Hangzhou) Co., Ltd. (hereinafter referred to as "Westlake Therapeutics") announced the completion of a new financing round exceeding RMB 100 million. This round was co-led by Beijing Shijingshan Modern Innovation Industry Development Fund Co., Ltd. ("Shijingshan Modern Innovation Industry Fund") and Ruili Synthetic Biology Fund, with follow-on participation from renowned industrial investors. Existing shareholders including Efung Capital, Huafang Capital, and Sequoia China continued to inject additional capital.

The proceeds from this financing round will be primarily utilized to advance the pipeline development of the company's red blood cell drug platform in therapeutic areas such as oncology and autoimmune diseases, accelerate the clinical validation and regulatory filing of core products, and further strengthen R&D, manufacturing, and industrialization capabilities.

Efung Capital participated in Westlake Therapeutics' financing rounds in both 2022 and 2025, serving as a core long-term shareholder accompanying the company's growth. Looking ahead, Efung Capital will continue to deepen strategic synergy with Westlake Therapeutics. Beyond capital support, we will leverage our extensive industrial resources and ecosystem network in the healthcare sector to help the company accelerate breakthroughs in the tumor immunotherapy and autoimmune disease arenas.